CORRELATION STUDY OF AGE, DISEASE DURATION, AND ERYTHROCYTE SEDIMENTATION RATE AMONG THE INDONESIAN RHEUMATOID ARTHRITIS PATIENTS
Objective: The present study aims to determine the correlation between age, disease duration, and erythrocyte sedimentation rate (ESR) among the Indonesian rheumatoid arthritis (RA) patients.
Methods: The subject was the Indonesian RA patients and healthy control subjects. We were determined the correlation between age, disease duration, and ESR usesÂ statistical analysis. The subjects who participated in the present study are patients who visit the RheumatologyÂ clinic at one governmental hospital in Bandung City, Indonesia. ESR was determined by the modified Westergrenâ€™s method. R software was conducted to data analysis.
Results: The number of subjects was 16.17% of men and 83.33% of women with the range from 20 to 77 y old. All patients received the combination of disease-modifying antirheumatic drugs, analgesic, andÂ corticosteroid. The average of disease duration was 8.08+5.73 y. The experimental ESR of the RA patients were 22.50+12.23 mm/h for men and 31.75+15.03 mm/h for women. This value is only slightly higher than the normal value.Â We suggested that treatment with combination therapy can maintain the ESR.
Conclusion: Spearman's correlation showed that there is no correlation between age and disease duration (rho = 0.325), between age and ESR (rho =-0.285), and between disease duration and ESR (rho = 0.039).
2. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky M, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
3. Schett G, Hayer S, Zwerina J, Redlich K, Smolen J. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1:47-54.
4. Emery P, Breedveld F, Dougados M, Kalden J, Schiff M, Smolen J. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
5. Furst D, Keystone E, Fleischmann R, Mease P, Breedveld F, Smolen J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2010;69:i2-29.
6. Silman A, Hochberg M. Epidemiology of the rheumatic diseases. 2 ed. New York: Oxford University Press; 2001.
7. Nainggolan O. Prevalensi dan determinan penyakit rematik di indonesia. Majalah Kedokteran Indonesia 2009;59:588-94.
8. Brigden M. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 1999;60:443-50.
9. Estridge B, Reynolds A, Walters N. Basic medical laboratory techniques. Albany, New York: Thomson Learning; 2000.
10. Lewis S. Miscellaneous tests. In: Lewis S, Bain B, Bates I. editors. Dacie and Lewis pactical haematology. 9 ed. London: Harcourt Publisher Ltd; 2001.
11. Initiative AAELARC. Rheumatoid arthritis classification criteria. Arthritis Rheum 2010;62:2569-81.
12. Gilmour D, Skyes A. Westergren and wintrobe methods of estimating E. S. R. compared. BMJ 1951;2:1496-506.
13. Samanci N, Ozdem S, Akbas H, Mutu D, Gultekin M, Arman M, et al. Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Natl Med Assoc 2005;97:1120-6.
14. Culoto M, Wilder R. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheumatic Disease Clinics North America 2000;26:825-39.
15. Salem M. Estrogen, a double-edged sword: modulation of Th1 and Th2 mediated inflamation by differential regulation of Th1/Th2 cytokines production. Current Drug Targets-Inflammation Allergy 2004;3:97-104.
16. Walker J, Littlejohn G, McMurray N, M MC. Stress system response and rhematoid arthritis: a multilevel approach. J Rheumatol 1999;38:50-7.
17. Chrousos G. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol 2004;106:S275-91.
18. Lipsky P. Rheumatoid arthritis. In: Dennis L, Anthony S, Dan L, Eugene B, Stephen L, Larry J. editors. Harrisonâ€™s principles of internal medicine. 16 ed. New York: McGraw Hill Company; 2005. p. 1968-76.
19. Choy E, Panayi G. Cytokine pathway and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
20. Harris E. Clinical features of rheumatoid arthtritis and their clinical significance. Arthritis Res 2002;4:S1-5.
21. Schuna A. Rheumatoid Arthritis. In: Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L. editors. Pharmacotherapy: A Pathophysiologic Approach. 7 ed. Singapore: Mc Graw Hill Medical; 2007.
22. Jou J, Lewis S, Briggs C. ICSH review of the measurement of erythrocyte sedimentation rate. Int J Laboratory Hematol 2011;33:125-32.
23. Bull B, Caswell M, Ernst E. ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993;46:198-203.
24. Bull B, Chien S, Dormandy J. Guidelines on selection of laboratory tests for monitoring the acute phase response. J Clin Pathol 1988;41:1203-12.
25. Koepke J, Bull B, Simson E. Reference and selected procedure for the erythrocyte sedimentation rate (ESR) test: Approved standard, NCCLS document H2-A4. In: Standards NCfCL. editor. 4 ed. PA: Wayne; 2000.
26. Gardner G. Laboratory testing in the rheumatic diseases: Erythrocyte sedimentation rate (ESR) University of Washington School of Medicine Online; 2001. Available from: www.uwcme.org/courses/rheumatology/rheumlab/esr.html-12k. [Last accessed on 01 Jul 2015].
27. Kushner I, Ballou S. Acute-phase reactants and the concept of inflammation. In: Firestein G, RC RB, Harris E, al e. editors. Kelleyâ€™sTextbook of Rheumatology. 8 ed. Philadelphia Saunders Elsevier; 2009.
28. Katzung B. Basic and Clinical Pharmacology. 9 ed. United State: McGraw-Hill Comp Inc; 2004.
29. Ibrahim O, Jirjees F, Mahdi H. Barriers affecting compliance of patients with chronic diseases: a preliminary study in united arab emirates (UAE) population. Asian J Pharm Clin Res 2011;4:42-5.